PEPFAR and AstraZeneca launch partnership across HIV and hypertension services in Africa

AstraZenecaThe U.S. President's Emergency Plan for AIDS Relief (PEPFAR) and biopharmaceutical company AstraZeneca have announced a $10 million (subject to the availability of funds), five-year global public-private partnership that will expand access to HIV/AIDS and hypertension services by offering them in an integrated manner at existing PEPFAR-supported HIV/AIDS sites, beginning in Kenya.

The new partnership, which supports the achievement of U.N. Sustainable Development Goal 3 (good health and well-being), is designed to address these challenges head-on by optimizing existing HIV/AIDS service delivery infrastructure and more specifically enhancing services for men aged 25-50. For AstraZeneca, PEPFAR's sizable patient reach presents an opportunity to screen for hypertension during clinical triage; for PEPFAR, the ability to make hypertension screening available to men alongside HIV/AIDS services supports efforts to identify harder-to-reach patients for HIV testing, specifically males aged 25-50, and provide appropriate referral to HIV/AIDS treatment. Through joint implementation, both programs will increase their impact and leverage existing program infrastructure to engage new patients in lifesaving treatment and care.

Mark Mallon, EVP International, member of the Senior Executive Team and Healthy Heart Africa (HHA) sponsor at AstraZeneca, said: "AstraZeneca shares PEPFAR's vision of improving the health and lives of underserved communities in sub-Saharan Africa. Increasing rates of hypertension and cardiovascular disease in the region threaten individuals, families and communities, and burden already-stressed health systems. We are honoured and proud to join with PEPFAR to improve access to vital testing and treatment which help stem the tide of both hypertension and HIV/AIDS."

Ambassador Deborah L. Birx, M.D., U.S. Global AIDS Coordinator and Special Representative for Global Health Diplomacy, said: "Together, we have made remarkable progress in the global response to HIV/AIDS. Yet, we need innovative approaches to better identify and serve harder to reach populations, including men, who too often only present for care when they are very ill. Through this new partnership with AstraZeneca we will enhance our ability to deliver earlier and more effective HIV/AIDS testing and treatment for working-age men in two high-prevalence counties in Kenya."

Data show that men often access HIV/AIDS testing and treatment at far lower rates than do women. For example, according to the most recent Kenya AIDS Indicator Survey, 79.8% of women surveyed had received an HIV test whereas only 62.5% of men had received one. This significant gender disparity leads to HIV-infected men entering care with more advanced disease, being less likely to receive lifesaving antiretroviral therapy (ART), and having higher mortality than HIV-infected women. Late diagnosis also results in missed opportunities for HIV prevention, including early ART initiation, resulting in ongoing transmission to previously uninfected partners.

AstraZeneca created Healthy Heart Africa (HHA) to support national governments in Africa in testing and scaling effective models of hypertension care, including treatment through access to discounted medicines. Since the program started in 2014, HHA and partners have screened almost 2 million people, trained more than 3,000 healthcare workers, and activated over 400 health facilities to provide hypertension services. HHA has identified new strategies for bringing hard-to-reach populations into hypertension care, including men between the ages of 25 and 50.

Hypertension and cardiovascular disease are two of the largest drivers of non-communicable diseases (NCDs) across Africa. Prevalence of hypertension in Africa has increased significantly over the past three decades. In 2000, there were approximately 80 million adults with hypertension in sub-Saharan Africa. Current epidemiological data suggest that this figure will rise to 150 million by 2025. In addition, evidence indicates that complications related to hypertension, in particular stroke and heart failure, are increasingly common in this region.

Launching in October 2016 with a one-year pilot program in Western Kenya, the partnership, in collaboration with the Kenyan Ministry of Health will leverage PEPFAR's existing HIV/AIDS infrastructure in Homa Bay and Kisumu. This area was identified due to the high burden for all patients but particularly working-age males who have not yet been reached by current HIV/AIDS programming. Longer term, the partnership aims to extend to other areas where the burden of both HIV/AIDS and hypertension is particularly high.

Subject to the availability of funds, it is intended that the initial pilot will be implemented by PATH, a Seattle-based PEPFAR partner with extensive expertise implementing both HIV and NCD programming. PATH is the leading implementing partner for the large-scale USAID APHIAplus programme, which integrates and improves health service delivery in Western and Nyanza regions of Kenya.

About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

About PEPFAR
The U.S. President's Emergency Plan for AIDS Relief (PEPFAR) was launched in 2003 and represents America's commitment to saving lives and the shared responsibility of all global partners to achieve an AIDS-free generation. PEPFAR is the largest effort by any nation to combat a single disease. With the generous support of the American people, the U.S. government has committed more than $70 billion to bilateral HIV/AIDS programs; the Global Fund to Fight AIDS, Tuberculosis and Malaria; and bilateral tuberculosis programs.

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Cells of 3 advanced cancers die with drug-like com…

Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggres...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]